

DATA SHEET

REAGENT	Omicron (BA.2) - infectious
REPOSITORY REFERENCE	101055
LOT NUMBER	28032022
DESCRIPTION	Omicron isolate grown in the Vero/hSLAM cell line. Originally isolated and passaged in the Vero/hSLAM cell line by UKHSA. Further propagated by NIBSC. Mycoplasma undetectable, sterility checked. FFU/mL in VeroE6: 2.40 x 1e5
PROVIDED	0.5mL of clarified culture supernatant

SEQUENCE

Variations called by both lofreq and ivar (>1%). In blue are BA.2 characteristic mutations (<https://outbreak.info>). All mutations are present. Details about the sequencing protocol is available on request.

User Ref: 101055	Version: 1.0	Version Date: 09/05/2022
Latest version of document available at: Q-DOCS		Date Printed: 10/05/2022 17:36
Document ID: 9310	Page 1 of 4	Issue Status: Published

National Institute for Biological Standards and Control

Position (NC_045512.2)	Ref	Alt	Proportion	Gene	Variation
241	C	T	0.999064	CHR_START-ORF1ab	n.241C>T
670	T	G	0.9994245	ORF1ab	p.Ser135Arg
2790	C	T	0.9990435	ORF1ab	p.Thr842Ile
3037	C	T	0.998663	ORF1ab	p.Phe924Phe
4184	G	A	0.998053	ORF1ab	p.Gly1307Ser
4321	C	T	0.9955705	ORF1ab	p.Ala1352Ala
4456	C	T	0.03928895	ORF1ab	p.Ala1397Ala
5059	T	C	0.01054725	ORF1ab	p.Tyr1598Tyr
9344	C	T	0.9991595	ORF1ab	p.Leu3027Phe
9424	A	G	0.9992045	ORF1ab	p.Val3053Val
9502	C	T	0.01114685	ORF1ab	p.Ala3079Ala
9534	C	T	0.9993495	ORF1ab	p.Thr3090Ile
9866	C	T	0.998857	ORF1ab	p.Leu3201Phe
10029	C	T	0.999271	ORF1ab	p.Thr3255Ile
10198	C	T	0.999567	ORF1ab	p.Asp3311Asp
10447	G	A	0.999344	ORF1ab	p.Arg3394Arg
10449	C	A	0.998823	ORF1ab	p.Pro3395His
11287	GTCTGGTTTT	G	0.972352	ORF1ab	p.Ser3675_Phe3677del
11750	C	T	0.998899	ORF1ab	p.Leu3829Phe
11873	G	A	0.01254075	ORF1ab	p.Val3870Ile
12880	C	T	0.9992	ORF1ab	p.Ile4205Ile
14408	C	T	0.999316	ORF1ab	p.Pro4715Leu
15714	C	T	0.999252	ORF1ab	p.Leu5150Leu
17410	C	T	0.999351	ORF1ab	p.Arg5716Cys
18163	A	G	0.9059355	ORF1ab	p.Ile5967Val
18675	A	C	0.0179231	ORF1ab	p.Arg6137Ser
19334	A	C	0.1210785	ORF1ab	p.Asp6357Ala
19955	C	T	0.99943	ORF1ab	p.Thr6564Ile
20055	A	G	0.999178	ORF1ab	p.Glu6597Glu
21618	C	T	0.9993295	S	p.Thr19Ile
21632	TTACCCCTG	T	0.9348615	S	p.Leu24_Ala27delinsSer
21987	G	A	0.999451	S	p.Gly142Asp
22200	T	G	0.998595	S	p.Val213Gly
22578	G	A	0.9996195	S	p.Gly339Asp
22674	C	T	0.998993	S	p.Ser371Phe
22679	T	C	0.999654	S	p.Ser373Pro
22686	C	T	0.9985855	S	p.Ser375Phe
22688	A	G	0.9990835	S	p.Thr376Ala
22775	G	A	0.9994345	S	p.Asp405Asn
22786	A	C	0.998506	S	p.Arg408Ser
22813	G	T	0.9995035	S	p.Lys417Asn
22882	T	G	0.999673	S	p.Asn440Lys
22992	G	A	0.9992	S	p.Ser477Asn
22995	C	A	0.9992705	S	p.Thr478Lys
23013	A	C	0.999297	S	p.Glu484Ala
23040	A	G	0.9994845	S	p.Gln493Arg
23055	A	G	0.9995365	S	p.Gln498Arg
23063	A	T	0.9997325	S	p.Asn501Tyr
23075	T	C	0.9996555	S	p.Tyr505His
23403	A	G	0.999534	S	p.Asp614Gly
23525	C	T	0.998893	S	p.His655Tyr
23599	T	G	0.9997635	S	p.Asn679Lys
23604	C	A	0.999144	S	p.Pro681His
23618	A	G	0.03485445	S	p.Ser686Gly
23854	C	A	0.9981625	S	p.Asn764Lys
23948	G	T	0.999316	S	p.Asp796Tyr
24424	A	T	0.999323	S	p.Gln954His
24469	T	A	0.9988135	S	p.Asn969Lys
25000	C	T	0.9992965	S	p.Asp1146Asp
25584	C	T	0.999477	ORF3a	p.Thr64Thr
26060	C	T	0.9995075	ORF3a	p.Thr223Ile
26270	C	T	0.999579	E	p.Thr9Ile
26283	AGTT	A	0.0198334	E	p.Val14del
26577	C	G	0.9994385	M	p.Gln19Glu
26709	G	A	0.99898	M	p.Ala63Thr
26858	C	T	0.9994785	M	p.Phe112Phe
27208	C	T	0.0111599	ORF6	p.His3Tyr
27219	C	T	0.01568735	ORF6	p.Asp6Asp
27230	CTATAGCAGAGATATTACTA ATTATTATGAGGACTTTTAAA GTTTCCATTGGAATCTTGAT	C	0.1605995	ORF6	p.Ile11fs
27233	T	C	0.110464	ORF6	p.Ile11Thr
27291	T	C	0.158366	ORF6	p.Asp30Asp
27382	G	C	0.9986835	ORF6	p.Asp61His
27383	A	T	0.9987985	ORF6	p.Asp61Val
27384	T	C	0.9988805	ORF6	p.Asp61Asp
27807	C	T	0.9993815	ORF7b	p.Leu18Leu
28271	A	T	0.9964825	ORF8-N	n.28271A>T
28311	C	T	0.999409	N	p.Pro13Leu
28361	GGAGAACGCA	G	0.8517315	N	p.Glu31_Ser33del
28881	G	A	0.998373	N	p.Arg203Lys
28882	G	A	0.998675	N	p.Arg203Arg
28883	G	C	0.999015	N	p.Gly204Arg
29510	C	C	0.998468	N	p.Ser413Arg
29733	CGAGGCCACGCGGAGTACGA TCGAGTG	C	0.808538	ORF10-CHR_END	n.29734_29759delGAGGCCACG CGGAGTACGATCGAGTG

APPLICATIONS Infectivity assay, viral growth, neutralisation assay.

DEPOSITOR Original virus received from Dr Kevin Bewley, UK Health Security Agency, Medical Interventions Group, Porton Down, UK. Further propagated and characterised by NIBSC.

ACKNOWLEDGMENTS Acknowledgment for publications should read "The following reagent was obtained from the Centre For AIDS Reagents, NIBSC, UK: Omicron - BA.2 (#101055), thanks to the contribution of Dr Kevin Bewley".

User Ref: 101055	Version: 1.0	Version Date: 09/05/2022
Latest version of document available at: Q-DOCS		Date Printed: 10/05/2022 17:36
Document ID: 9310	Page 3 of 4	Issue Status: Published

MATERIAL SAFETY SHEET

Physical properties (at room temperature)			
Physical appearance	Yellow/Pink, liquid		
Fire hazard	None		
Chemical properties			
Stable	Yes	Corrosive:	No
Hygroscopic	No	Oxidising:	No
Flammable	No	Irritant:	No
Other: Live SARS-CoV-2. It is the responsibility of the end user to seek local biosafety approval for the storage and handling of the material in their workplace			
Handling: CAUTION - This preparation is not for administration to humans or animals in the human food chain. This preparation is hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective clothing, gloves and use within ACDP3 or higher facility.			
Toxicological properties			
Effects of inhalation:	Likelihood of Coronavirus infection		
Effects of ingestion:	Likelihood of Coronavirus infection		
Effects of skin absorption:	Not established, avoid contact with skin		
Suggested First Aid			
Inhalation	Seek medical advice		
Ingestion	Seek medical advice		
Contact with eyes	Wash with copious amounts of water. Seek medical advice.		
Contact with skin	Wash thoroughly with water.		
Action on Spillage and Method of Disposal			
Spillage of contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate virucidal agent followed by water. Absorbent materials used to treat spillage should be treated as biologically hazardous waste.			

User Ref: 101055	Version: 1.0	Version Date: 09/05/2022
Latest version of document available at: Q-DOCS		Date Printed: 10/05/2022 17:36
Document ID: 9310	Page 4 of 4	Issue Status: Published